Momelotinib Improves Symptoms of Myelofibrosis
The proportion of patients with a 50% or greater reduction in total symptom score was higher with momelotinib than with danazol.
Diagnosis & Disease Information
Monoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
Venetoclax Plus Azacitidine Appears Promising in High-Risk MDS, CMML
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Study Advances Knowledge Base About Children, Young Adults With MPNs
Researchers uncovered higher-than-anticipated rates of thrombosis, hemorrhage, and disease transformation in a real-world cohort of young MPN patients.
Certain Blood Cancer Patients Do Not Seroconvert After a Third COVID-19 Vaccine Dose
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib.
Mobile Exercise App Feasible During Outpatient Chemotherapy for Myeloid Neoplasms
A mobile app that tracks exercise is feasible for older patients receiving chemotherapy for myeloid neoplasms.
Cancer Guidelines May Ease Disease-Specific Fatigue in Patients With Myeloproliferative Neoplasms
Established general guidelines for cancer-related fatigue may help patients with myeloproliferative neoplasms.
The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasms
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
SARS-CoV-2 Vaccination Reduces Risk of Mortality and Hospitalization in MPNs
A single-center study sought to determine the effects of SARS-CoV-2 vaccination in patients with myeloproliferative neoplasms.
- Loading...
Loading...
Next post in EHA 2022
Loading... 
Loading...